---
document_datetime: 2025-12-02 04:54:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xofigo.html
document_name: xofigo.html
version: success
processing_time: 0.1168247
conversion_datetime: 2025-12-28 00:41:19.195904
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xofigo

[RSS](/en/individual-human-medicine.xml/65913)

##### Authorised

This medicine is authorised for use in the European Union

radium Ra223 dichloride Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Xofigo](#news-on)
- [More information on Xofigo](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Xofigo is a radiopharmaceutical (a medicine containing a radioactive substance) that is used to treat adults with cancer of the prostate (a gland of the male reproductive system).

Xofigo is used when castration (to stop the production of male hormones) by surgery or with medicines does not work, and when the cancer has spread to the bones (bone metastases) and is causing symptoms such as pain, but has not spread to other internal organs. It should be used only for patients who have had at least two previous treatments for prostate cancer or who cannot receive other treatments.

Xofigo is used on its own or in combination with a medicine known as an 'LHRH analogue'.

Xofigo contains the active substance radium-223 dichloride.

Expand section

Collapse section

## How is Xofigo used?

Xofigo can only be obtained with a prescription and should only be handled and given by someone who is authorised to use radioactive medicines and after evaluation of the patient by a qualified doctor.

The dose of Xofigo is calculated to provide a specific dose of radioactivity based on the patient's body weight. The medicine is slowly injected into a vein usually for up to one minute. Injections are repeated every 4 weeks for a total of 6 injections.

For more information about using Xofigo, see the package leaflet or contact your doctor or pharmacist.

## How does Xofigo work?

The active substance in Xofigo, radium-223, emits short-range radiation known as alpha particles. The bones in the body take up radium in the same way as calcium. The radioactive radium builds up in bone tissues where the cancer has spread, and the alpha particles destroy surrounding cancer cells and help to control the associated symptoms.

## What benefits of Xofigo have been shown in studies?

Xofigo was compared with placebo (a dummy treatment) as an addition to standard care in a main study involving 921 men with cancer of the prostate that had spread to the bones and for which suppression of male hormones using medicines or surgery did not work. Patients were given up to 6 injections at 1-month intervals and were followed up for 3 years from the first injection. Patients given Xofigo lived on average for 14.9 months, compared with 11.3 months for those given placebo. The signs and symptoms of progressive disease such as bone pain also took longer to develop in patients given Xofigo.

## What are the risks associated with Xofigo?

The most common side effects with Xofigo (which may affect more than 1 in 10 people) are diarrhoea, nausea (feeling sick), vomiting, thrombocytopenia (low blood-platelet counts) and bone fractures. The most serious side effects were thrombocytopenia and neutropenia (low levels of neutrophils, a type of white blood cell that fights infection). For the full list of side effects of Xofigo, see the package leaflet.

Xofigo must not be used with the medicine abiraterone acetate and the corticosteroids prednisone or prednisolone. For the full list of restrictions, see the package leaflet.

## Why is Xofigo authorised in the EU?

The European Medicines Agency decided that Xofigo's benefits are greater than its risks and it can be authorised for use in the EU. Xofigo has been shown to prolong life and delaying signs and symptoms of progressive disease. Regarding its safety, several measures have been put in place to minimise the risks of the medicine such as bone fractures 1 . The radiation emitted by Xofigo has a shorter range than the radiation of currently available radiopharmaceuticals. This may limit the damage to nearby healthy tissues.

1 See [outcome of safety review carried out in 2018](/en/news/ema-restricts-use-prostate-cancer-medicine-xofigo) .

## What measures are being taken to ensure the safe and effective use of Xofigo?

Xofigo can increase the risk of having fractures. The company that markets Xofigo will have to conduct studies to further characterise the safety profile of the medicine, in particular with regard to the risk of fractures and the risk of new metastases that do not affect the bone in patients treated with Xofigo.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xofigo have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Xofigo are continuously monitored. Side effects reported with Xofigo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Xofigo

Xofigo received a marketing authorisation valid throughout the EU on 13 November 2013

Xofigo : EPAR - Medicine overview

Reference Number: EMA/676704/2018

English (EN) (77.16 KB - PDF)

**First published:** 28/11/2013

**Last updated:** 11/10/2018

[View](/en/documents/overview/xofigo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-656)

български (BG) (103.58 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/bg/documents/overview/xofigo-epar-medicine-overview_bg.pdf)

español (ES) (76.74 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/es/documents/overview/xofigo-epar-medicine-overview_es.pdf)

čeština (CS) (100.55 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/cs/documents/overview/xofigo-epar-medicine-overview_cs.pdf)

dansk (DA) (76.06 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/da/documents/overview/xofigo-epar-medicine-overview_da.pdf)

Deutsch (DE) (77.74 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/de/documents/overview/xofigo-epar-medicine-overview_de.pdf)

eesti keel (ET) (74 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/et/documents/overview/xofigo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (107.47 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/el/documents/overview/xofigo-epar-medicine-overview_el.pdf)

français (FR) (77.7 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/fr/documents/overview/xofigo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (95.49 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/hr/documents/overview/xofigo-epar-medicine-overview_hr.pdf)

italiano (IT) (75.93 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/it/documents/overview/xofigo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (105.89 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/lv/documents/overview/xofigo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (97.99 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/lt/documents/overview/xofigo-epar-medicine-overview_lt.pdf)

magyar (HU) (95.1 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/hu/documents/overview/xofigo-epar-medicine-overview_hu.pdf)

Malti (MT) (100.93 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/mt/documents/overview/xofigo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (76.44 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/nl/documents/overview/xofigo-epar-medicine-overview_nl.pdf)

polski (PL) (100.95 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/pl/documents/overview/xofigo-epar-medicine-overview_pl.pdf)

português (PT) (76.7 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/pt/documents/overview/xofigo-epar-medicine-overview_pt.pdf)

română (RO) (104.49 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/ro/documents/overview/xofigo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (99.01 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/sk/documents/overview/xofigo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (94.53 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/sl/documents/overview/xofigo-epar-medicine-overview_sl.pdf)

Suomi (FI) (75.5 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/fi/documents/overview/xofigo-epar-medicine-overview_fi.pdf)

svenska (SV) (76.22 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

11/10/2018

[View](/sv/documents/overview/xofigo-epar-medicine-overview_sv.pdf)

Xofigo : EPAR - Risk management plan

English (EN) (5.47 MB - PDF)

**First published:** 16/05/2023

**Last updated:** 28/07/2025

[View](/en/documents/rmp/xofigo-epar-risk-management-plan_en.pdf)

## Product information

Xofigo : EPAR - Product Information

English (EN) (509.92 KB - PDF)

**First published:** 28/11/2013

**Last updated:** 28/07/2025

[View](/en/documents/product-information/xofigo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-113)

български (BG) (870.99 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/bg/documents/product-information/xofigo-epar-product-information_bg.pdf)

español (ES) (928.6 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/es/documents/product-information/xofigo-epar-product-information_es.pdf)

čeština (CS) (1020.35 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/cs/documents/product-information/xofigo-epar-product-information_cs.pdf)

dansk (DA) (747.78 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/da/documents/product-information/xofigo-epar-product-information_da.pdf)

Deutsch (DE) (850.92 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/de/documents/product-information/xofigo-epar-product-information_de.pdf)

eesti keel (ET) (737.39 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/et/documents/product-information/xofigo-epar-product-information_et.pdf)

ελληνικά (EL) (827.68 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/el/documents/product-information/xofigo-epar-product-information_el.pdf)

français (FR) (688.73 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/fr/documents/product-information/xofigo-epar-product-information_fr.pdf)

hrvatski (HR) (621.29 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/hr/documents/product-information/xofigo-epar-product-information_hr.pdf)

íslenska (IS) (770.19 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/is/documents/product-information/xofigo-epar-product-information_is.pdf)

italiano (IT) (803.97 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/it/documents/product-information/xofigo-epar-product-information_it.pdf)

latviešu valoda (LV) (993.42 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/lv/documents/product-information/xofigo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1002.44 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/lt/documents/product-information/xofigo-epar-product-information_lt.pdf)

magyar (HU) (1.02 MB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/hu/documents/product-information/xofigo-epar-product-information_hu.pdf)

Malti (MT) (1.01 MB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/mt/documents/product-information/xofigo-epar-product-information_mt.pdf)

Nederlands (NL) (756.91 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/nl/documents/product-information/xofigo-epar-product-information_nl.pdf)

norsk (NO) (753.52 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/no/documents/product-information/xofigo-epar-product-information_no.pdf)

polski (PL) (1013.99 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/pl/documents/product-information/xofigo-epar-product-information_pl.pdf)

português (PT) (939.96 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/pt/documents/product-information/xofigo-epar-product-information_pt.pdf)

română (RO) (1000.59 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/ro/documents/product-information/xofigo-epar-product-information_ro.pdf)

slovenčina (SK) (675.94 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/sk/documents/product-information/xofigo-epar-product-information_sk.pdf)

slovenščina (SL) (1002.37 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/sl/documents/product-information/xofigo-epar-product-information_sl.pdf)

Suomi (FI) (946.74 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/fi/documents/product-information/xofigo-epar-product-information_fi.pdf)

svenska (SV) (742.24 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

28/07/2025

[View](/sv/documents/product-information/xofigo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000281776 28/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xofigo : EPAR - All Authorised presentations

English (EN) (23.05 KB - PDF)

**First published:** 28/11/2013

**Last updated:** 16/10/2015

[View](/en/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-402)

български (BG) (29.94 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/bg/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_bg.pdf)

español (ES) (10.2 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/es/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.79 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/cs/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (10.17 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/da/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (10.17 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/de/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (10.13 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/et/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (28.71 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/el/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_el.pdf)

français (FR) (10.16 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/fr/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (20.94 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/hr/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (10.19 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/is/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (10.22 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/it/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (21.3 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/lv/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (22.71 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/lt/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (15.75 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/hu/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (23.01 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/mt/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (11.48 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/nl/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (10.17 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/no/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_no.pdf)

polski (PL) (21.62 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/pl/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_pl.pdf)

português (PT) (10.23 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/pt/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_pt.pdf)

română (RO) (20.46 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/ro/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (21.27 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/sk/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (15.76 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/sl/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (11.41 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/fi/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (10.19 KB - PDF)

**First published:**

28/11/2013

**Last updated:**

16/10/2015

[View](/sv/documents/all-authorised-presentations/xofigo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xofigo Active substance radium (223Ra) dichloride International non-proprietary name (INN) or common name radium Ra223 dichloride Therapeutic area (MeSH) Prostatic Neoplasms Anatomical therapeutic chemical (ATC) code V10XX03

### Pharmacotherapeutic group

Therapeutic radiopharmaceuticals

### Therapeutic indication

Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

## Authorisation details

EMA product number EMEA/H/C/002653

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Bayer AG

51368 Leverkusen

Marketing authorisation issued 13/11/2013 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xofigo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.63 KB - PDF)

**First published:** 28/07/2025

[View](/en/documents/procedural-steps-after/xofigo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Xofigo : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (168.34 KB - PDF)

**First published:** 07/05/2014

**Last updated:** 28/07/2025

[View](/en/documents/procedural-steps-after/xofigo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Xofigo : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

English (EN) (112.37 KB - PDF)

**First published:** 07/07/2022

[View](/en/documents/scientific-conclusion/xofigo-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Xofigo-H-A-20-1459-C-002653-0028 : EPAR - Assessment report - Article 20

Adopted

Reference Number: EMA/540557/2018

English (EN) (1.62 MB - PDF)

**First published:** 11/10/2018

[View](/en/documents/variation-report/xofigo-h-20-1459-c-002653-0028-epar-assessment-report-article-20_en.pdf)

Xofigo-H-A-20-1459-C-002653-0028 : EPAR - Assessment report on provisional measures - Article 20

Reference Number: EMA/170170/2018

English (EN) (916.85 KB - PDF)

**First published:** 21/03/2018

**Last updated:** 21/03/2018

[View](/en/documents/variation-report/xofigo-h-20-1459-c-002653-0028-epar-assessment-report-provisional-measures-article-20_en.pdf)

Xofigo-H-C-PSUSA-10132-201611 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/557197/2017

English (EN) (67.51 KB - PDF)

**First published:** 24/08/2017

**Last updated:** 24/08/2017

[View](/en/documents/scientific-conclusion/xofigo-h-c-psusa-10132-201611-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Xofigo : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/578779/2013

English (EN) (1.57 MB - PDF)

**First published:** 28/11/2013

**Last updated:** 28/11/2013

[View](/en/documents/assessment-report/xofigo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Xofigo

Reference Number: EMA/CHMP/411215/2013

English (EN) (69.96 KB - PDF)

**First published:** 20/09/2013

**Last updated:** 20/09/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-xofigo_en.pdf)

#### News on Xofigo

[EMA restricts use of prostate cancer medicine Xofigo](/en/news/ema-restricts-use-prostate-cancer-medicine-xofigo) 27/07/2018

[Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone](/en/news/prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-prednisone-prednisolone) 09/03/2018

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 November 2017](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-november-2017) 01/12/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2013) 20/09/2013

#### More information on Xofigo

- [Xofigo - supply shortage](/en/medicines/human/shortages/xofigo)
- [EMEA-001986-PIP01-16 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001986-pip01-16)
- [Xofigo - referral](/en/medicines/human/referrals/xofigo)
- [URANIS -Data collection in urological centers during treatment with Ra-223 dichloride (Xofigo) within the framework of a non-interventional study assessing overall survival (OS) and effectiveness predictors of Ra-223 dichloride treated mCRPC patients in a real life setting in Germany - post-authorisation study](https://catalogues.ema.europa.eu/study/43099)
- [Drug utilisation study of Radium 223 under routine clinical practice in Europe (DIRECT) - post-authorisation study](https://catalogues.ema.europa.eu/study/46942)
- [PRECISE/Rates of bone fractures and survival in metastatic castration-resistant PRostate cancer (mCRPC) PatiEnts treated with Radium-223 in routine Clinical practIce in SwedEn - post-authorisation study](https://catalogues.ema.europa.eu/study/42249)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/07/2025

## Share this page

[Back to top](#main-content)